Table 1. Summary of 19 studies included.
| Source | Sample sizea | Cancer type(s) | Attitudes toward AIb use in cancer care | ||||
|---|---|---|---|---|---|---|---|
| AI versus physicianc | Patient outlookd |
Trustd | Satisfactiond | Feard | |||
| Au et al, 2023 [28] | 1 | Choroidal metastasis | N/Ae | N/A | N/A | + | N/A |
| Fransen et al, 2025 [29] | 206 | Prostate cancer | Combined | N/A | + | N/A | N/A |
| Goessinger et al, 2024 [30] | 205 | Melanoma | Combined | N/A | + | N/A | − |
| Hildebrand et al, 2023 [31] | 15 | Metastatic cancer | Combined | +, − | + | N/A | N/A |
| Jutzi et al, 2020 [17] | 154 | Melanoma | Combined | +, − | N/A | N/A | N/A |
| Kenig et al, 2024 [32] | 20 | Breast cancer | N/A | N/A | + | N/A | N/A |
| Klotz et al, 2024 [33] | 17 | Pancreatic cancer | N/A | N/A | N/A | + | N/A |
| Lee et al, 2020 [34] | 285 | Breast, colorectal, gastric, gynecological, liver, lung, thyroid | N/A | N/A | N/A | + | N/A |
| Leung et al, 2022 [35] | 48 | Breast, gynecological, colorectal, head and neck | N/A | N/A | N/A | + | N/A |
| Lysø et al, 2024 [36] | 30 | Prostate cancer | Combined | +, − | N/A | N/A | + |
| Manolitsis et al, 2023 [37] | NA | Prostate cancer | N/A | N/A | + | N/A | N/A |
| McCradden et al, 2020 [38] | 18 | Meningioma | N/A | − | U | N/A | N/A |
| Nally et al, 2024 [39] | 28 | Colorectal | Combined | +, − | - | N/A | + |
| Nelson et al, 2020 [18] | 32 | Melanoma, nonmelanoma skin cancer | Combined | +, − | N/A | N/A | N/A |
| Rodler et al, 2024 [40] | 257 | Prostate cancer | Combined | N/A | + | N/A | N/A |
| Šafran et al, 2024 [41] | 166 | Breast, colorectal | N/A | N/A | N/A | + | N/A |
| Temple et al, 2023 [42] | 95 | N/A | N/A | − | − | N/A | N/A |
| van Bussel et al, 2022 [43] | 135 | Breast, colorectal, gynecological, N/A | N/A | + | U | N/A | N/A |
| Yang et al, 2019 [19] | 402 | Lung, breast, pharyngeal, lymphoma, othersf | Combined | +, − | N/A | N/A | N/A |
Patient population with cancer in the included study only. For detailed information on participant size and characteristics, please see Multimedia Appendix 2.
AI: artificial intelligence.
Sources were identified as either having a patient attitude that prefers AI, a physician, or a combined AI plus physician model.
Predominant attitudes in each paper are indicated by positive (+), negative (−), or undefined (U) to describe patients’ feelings with respect to the given attitude.
N/A: not applicable or not assessed.
The top 4 types of cancer included in the study have been included in this list. For more detailed information, please see Multimedia Appendix 2.